Author:
Staedtke Verena,Bai Ren-Yuan,Blakeley Jaishri O’Neill
Funder
Francis S. Collins Scholar Program
Children's Tumor Foundation
National Cancer Institute
Neurofibromatosis Therapeutic Acceleration Program
Bloomberg and Gottesman Foundation
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Clinical Neurology,Pharmacology
Reference73 articles.
1. Carey JC, Baty BJ, Johnson JP, Morrison T, Skolnick M, Kivlin J. The genetic aspects of neurofibromatosis. Ann N Y Acad Sci 1986; 486: 45-56.
2. NIH. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13–15, 1987. Neurofibromatosis 1988; 1: 172-178.
3. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278: 51-57.
4. Abramowicz A, Gos M. Neurofibromin in neurofibromatosis type 1—mutations in NF1gene as a cause of disease. Dev Period Med 2014; 18: 297-306.
5. Ratner N, Miller SJ. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer 2015; 15: 290-301.
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献